Position in SYRE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$5,044,000
+$1,768,000 QoQ
Shares Held
100,000
0.0% QoQ
Ownership
0.115%
of shares outstanding
% of Portfolio
3.74%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026B Group, Inc. holds $131,230,508 across 19 Biotechnology names. SYRE ranks #10 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ADMA |
Adma Biologics, Inc.
|
3,207,542 | $28,899,953 | |
| 2 | PALI |
Palisade Bio, Inc.
|
11,414,285 | $19,974,998 | |
| 3 | PRAX |
Praxis Precision Medicines, Inc.
|
33,237 | $10,708,629 | |
| 4 | CLLS |
Cellectis S.A.
|
3,281,501 | $10,402,358 | |
| 5 | ZLAB |
Zai Lab Ltd
|
450,646 | $8,476,651 | |
| 6 | TSHA |
Taysha Gene Therapies, Inc.
|
1,800,556 | $8,048,485 | |
| 7 | NRXP |
NRX Pharmaceuticals, Inc.
|
3,000,000 | $6,390,000 | |
| 8 | GPCR |
Structure Therapeutics Inc.
|
127,500 | $6,145,500 |
All Filings in SYRE
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,044,000 | 100,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,276,000 | 100,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,676,000 | 100,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,197,600 | 80,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,129,450 | 70,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,164,000 | 50,000 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||